Clinical trials: Type II Diabetic Patients With Nephropathy
Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
Phase II Pharmacodynamic Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease
This study assesses the effects of a new formulation of bardoxolone methyl on eGFR in Patients with Chronic Kidney Disease and Type 2 Diabetes.
- Trial name
- NCT01053936
- Testing
- Bardoxolone methyl (amorphous dispersion)
- Where
- 26 sites in United States
- Volunteers
- 129 people
- Sponsor
- Biogen
Sleep Apnea, Diabetic Nephropathy Type 2
Sleep Apnea, Coronary Atherosclerosis and Heart Failure in Diabetes Patients With Nephropathy
Background: Diabetes, and especially diabetic kidney disease is associated with the development of cardiovascular disease such as calcification in the coronary arteries and heart failure.
- Conditions
- Sleep Apnea, Diabetic Nephropathy Type 2, Coronary Atheroscleroses, Heart Insufficiency
- Trial name
- SLEEP (NCT04549324)
- Where
- Denmark
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Diabetes Mellitus, Type 2, Diabetes Complications
The Use of Cilostazol in Patients With Diabetic Nephropathy
Patients with type 2 diabetes have a long duration of disease for the development of complications. Among all complications, microangiopathic complications are major causes of mortality and morbidity in diabetic patients.
- Trial name
- NCT00272831
- Testing
- Cilostazol
- Volunteers
- 62 people
- Sponsor
- Chinese University of Hong Kong
Type 2 Diabetes
Renal Effects of DPP-4 Inhibitor Linagliptin in Type 2 Diabetes
The aim of this study is to detail the (mechanisms underlying the) actions of the DPP-4 inhibitor linagliptin on the renal system in patients with type 2 diabetes mellitus.
- Trial name
- RENALIS (NCT02106104)
- Testing
- Linagliptin 5 mg QD (N=24), Glimepiride 1 mg QD (N=24)
- Where
- Netherlands
- Volunteers
- 48 people
- Sponsor
- Amsterdam UMC, location VUmc
Diabetic Kidney Disease, Diabetes Mellitus, Type 2
EMPRA (EMPagliflozin and RAs in Kidney Disease)
This study will be a prospective, clinical pilot study in CKD patients to show whether Empagliflozin in addition to ACEi treatment significantly increases Ang 1-7 levels compared to ACEi treatment alone.
- Conditions
- Diabetic Kidney Disease, Diabetes Mellitus, Type 2, Chronic Kidney Disease stage3, Chronic Kidney Disease stage4
- Trial name
- EMPRA (NCT03078101)
- Testing
- Empagliflozin 10 MG [Jardiance]
- Where
- Austria
- Volunteers
- 51 people
- Sponsor
- Medical University of Vienna
Diabetic Nephropathies
Phase IIb Clinical Trial for the Efficacy and Safety by CU01-1001 for 24 Weeks in Type 2 DM Patients With Albuminuria
To evaluate the efficacy and safety of CU01-1001 administered for 24 weeks in type 2 diabetic nephropathy patients with albuminuria.
- Trial name
- NCT05718375
- Testing
- CU01-1001
- Where
- 24 sites in South Korea
- Volunteers
- 240 people
- Sponsor
- Curacle Co., Ltd.
Diabetic Nephropathy
The Effects of Bindarit in Diabetic Nephropathy
The purpose of this study is to determine whether bindarit is effective to reduce albuminuria, compared to placebo, in nephropathic patients treated with irbesartan, as a background therapy.
- Trial name
- NCT01109212
- Testing
- Bindarit
- Where
- 6 sites in Italy, Slovenia
- Volunteers
- 100 people
- Sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.A
Type 2 Diabetic Nephropathy
A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy
PF-03882845 is a compound proposed for treatment of type 2 diabetic nephropathy. The primary purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics of multiple doses of PF-03882845…
- Trial name
- NCT01488877
- Testing
- PF-03882845, Spironolactone
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Pfizer
Diabetic Foot, Type 2 Diabetes Mellitus With Established Diabetic Nephropathy
The Effectiveness of Improving Self-care After Counseling for the Diabetics Mellitus Foots Around Chiayi Region
Objectives: Preventing diabetic foot problems (DFP) and associated consequences, such as amputation, is a critical in rural regions.
- Trial name
- NCT01299246
- Testing
- Michigan Neuropathy Screening Instrument
- Where
- Taiwan
- Volunteers
- 386 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Diabetic Kidney Disease, Type2 Diabetes
Determining Serum and Urinary Levels of miRNA 192 and miRNA 25 in Patients With and Without Type 2 Diabetes.
Diabetes kidney disease (DKD) is the leading cause of end stage renal disease (ESRD) in western countries and its incidence is worryingly increasing worldwide.
- Trial name
- NCT04176276
- Testing
- no interventions required.
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- University of Pisa
Diabetic Kidney Disease
Antiproteinuric Effects of Liraglutide Treatment
The purpose of the study is to determine the effect of Liraglutide on albuminuria in type 2 diabetes.
- Trial name
- LIRALBU (NCT02545738)
- Testing
- Liraglutide
- Where
- Denmark
- Volunteers
- 32 people
- Sponsor
- Steno Diabetes Center Copenhagen
Chronic Kidney Disease, Diabetic Kidney Disease
A Trial to Learn More About How BAY2327949 Works and How Safe it is in Patients Whose Kidneys Are Damaged Due to High Blood Sugar Levels or High Blood Pressures, and With a Further Disease of the Heart or the Blood Vessels.
In people with type 2 diabetes (T2D), the body makes insulin, but cannot use it well. This results in high blood sugar levels causing damage to the blood vessels inside the kidneys.
- Trial name
- ASSESS-CKD (NCT04661917)
- Testing
- BAY2327949
- Where
- 36 sites in Austria, Denmark and 5 more
- Sponsor
- Bayer
Chronic Kidney Disease, Type 2 Diabetes
Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease
This study assesses the effects of bardoxolone methyl (RTA 402) in patients with type 2 diabetes and chronic kidney disease.
- Conditions
- Chronic Kidney Disease, Type 2 Diabetes, Diabetic Nephropathy
- Trial name
- NCT00811889
- Testing
- Bardoxolone Methyl (RTA 402)
- Where
- 42 sites in United States
- Volunteers
- 227 people
- Sponsor
- Biogen
Diabetic Nephropathy, Type 2 Diabetes Mellitus
ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial
The purpose of the study is to evaluate the effectiveness and safety of olmesartan versus placebo on the progression of diabetic renal disease.
- Conditions
- Diabetic Nephropathy, Type 2 Diabetes Mellitus, Proteinuria
- Trial name
- NCT00141453
- Testing
- olmesartan medoxomil
- Where
- 2 sites in China, Japan
- Volunteers
- 577 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Diabetic Nephropathy
Open Label Tolerability and Safety Study of KRX-101 in Australia, New Zealand, and Hong Kong
The purpose of this study is to assess the tolerability and safety of KRX-101 in treating persistent microalbuminuria in type 2 diabetic patients who are also being treated with stable, maximum tolerated doses of either ACE…
- Trial name
- NCT00462202
- Testing
- sulodexide
- Where
- Australia
- Volunteers
- 200 people
- Sponsor
- Keryx Biopharmaceuticals
Type 2 Diabetes With Renal Manifestations
Predictors of Chronic Kidney Disease Among Type 2 Diabetic Patients in Assiut University Hospitals
Predictors of Chronic Kidney Disease among Type 2 Diabetic Patients in Assiut University Hospitals.
- Trial name
- Ckd&dm (NCT05847400)
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Assiut University
Diabetic Nephropathies, Diabetes Mellitus, Type 2
Comparing The Effect Of Empagliflozin With Dapagliflozin In Reducing Proteinuria In Diabetic Patients With Chronic Kidney Disease With eGFR More Than 45ml/Min/1.73m²
This study was designed to compare empagliflozin and dapagliflozin in reducing protein leakage into the urine in adults with type 2 diabetes and chronic kidney disease.
- Conditions
- Diabetic Nephropathies, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic
- Trial name
- NCT07866235
- Testing
- Dapagliflozin, Empagliflozin (EMPA)
- Where
- Pakistan
- Volunteers
- 116 people
- Sponsor
- Lahore General Hospital
Diabetic Kidney Disease
Decision Impact Trial of KidneyIntelX
The current trial is designed to evaluate how the results of KidneyIntelX test impacts on the clinical management of type 2 diabetes patients identified as increased risk for rapid kidney function decline within 5-years.
- Trial name
- NCT04791358
- Testing
- KidneyIntelX
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- Renalytix AI, Inc.
Diabetic Nephropathy Type 2, Albuminuria
Dietary Interventions on Glycocalyx Dimensions in South Asian Patients With Diabetic Nephropathy.
Evaluate the effect of a fasting mimicking diet and a food supplement on the microvascular health and urinary heparanase levels in South Asian type 2 diabetic patients with albuminuria.
- Conditions
- Diabetic Nephropathy Type 2, Albuminuria, Type2 Diabetes Mellitus, Glucose Metabolism Disorders
- Trial name
- Glycotreat (NCT03889236)
- Testing
- Fasting mimicking diet Prolon, Food supplement Endocalyx
- Where
- Netherlands
- Volunteers
- 56 people
- Sponsor
- Leiden University Medical Center
Diabetic Kidney Disease, Diabetic Nephropathy
Effect of LIXIsenatide on the Renal System
Based on preclinical and small-sized studies in non-diabetic individuals, incretin-based therapies, i.e. glucagon-like peptide (GLP)-1 receptor agonists and dipeptidyl peptidase-4 inhibitors, may hold promise in preventing the…
- Conditions
- Diabetic Kidney Disease, Diabetic Nephropathy, Diabetes Mellitus, Glucagon-Like Peptide 1
- Trial name
- ELIXIRS (NCT02276196)
- Testing
- Lixisenatide, Insulin glulisine
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Amsterdam UMC, location VUmc